Blood Groups and Antibodies, Transfusion and Pregnancy

Debbie Asher EPA Network Transfusion Laboratory Manager

To cover:

- What is a red cell antigen?
- What is a red cell antibody?
- Haemolytic Disease of the Newborn
 - Monitoring pregnancies
 - Preventing HDN, particularly through antenatal anti-D prophylaxis
 - Predicting outcomes
 - Difficult interpretations and working together
- The Direct Antiglobulin Test (DAT/DCT)

An Antigen

- An antigen can be defined as a <u>substance</u> that, when introduced into the circulation of an individual lacking that antigen, can <u>stimulate the production of</u> <u>a specific antibody</u>.
- Red cell antigens

Blood Group Antigens



ABO Antigens



A Close Up



The D Antigen

- Most individuals are D positive or D negative
- An individual may have a weak D antigen (previously known as D^u).
- An individual may have a partial D antigen (previously known as a D^{variant}).

RhD



Inheritance





An Antibody

 An antibody can be defined as a serum protein (*i.e.* an immunoglobulin with specific antigen binding sites) produced as a result of the introduction of a **foreign** antigen, that has the ability to combine with (and, in many cases, destroy) the cells carrying the antigen that stimulated its production



Antibodies - IgG

Immunoglobulin IgG subclasses



Red Cell Antibodies

Produced when exposed to foreign **blood**:

- Previous transfusion of blood/components
- Fetal maternal haemorrhage

ABO System

Red Cells (Antigens) Plasma (Antibodies)



- B
- 0
- AB

- Anti-B
- Anti-A
- Anti-A,B
 - None

Haemolytic Disease of the Fetus and Newborn

- Is a condition in which the lifespan of the infant's red cells is shortened by the action of specific antibodies derived from the mother by placental transfer.
- Anaemia, jaundice, liver damage, kernicterus, IUD

Serological Testing During Pregnancy

Purpose:

- Identify RhD negative individuals so that appropriate anti-D prophylaxis can be given to prevent HDN due to anti-D
- To identify those at risk of HDN
- To predict the severity of the HDN to plan treatment

Maternal Monitoring

- Booking bloods
 - ABO, D type and antibody screen
- Repeat test at 28 weeks
 - Confirm ABO and D type, repeat antibody screen
- If antibodies detected
 - Identify and monitor, regime dependent upon antibody

The Big Three

- Anti-D, anti-c and anti-K
- Test monthly up to 28 weeks
- Test every 2 weeks up to delivery
- Anti-D and anti-c are quantitated against a National Standard with results in IU/mL
- Anti-K is titrated
- Current sample is tested in parallel with previous sample to accurately identify changes in antibody level

Sample NHSBT Report 1

National Blood Service - Re	ed Cell Ir	nmunohaematolog	¥ Ria	MIS
	Patient:		Sample No:	og ang transplant
HOSPITAL TRANSFUSION LABORATORY	DoB:		NHSBT No:	
HOSPITAL	Hospital No:	1	Taken:	17-May-2012
COLNEY LANE COLNEY	Address:		Received:	21-May-2012 09:02:19
NORFOLK		-	Reported:	23-May-2012
NR4 701			Hosp Sample ID:	
Primary Requesting Clinician: xxxxxxxx1 HEAD OF BLOOD TRANSFUSION	EDD: Gestation	21-Nov-2012 14 weeks		

O RhD negative

Red	Cell	Antiboo	ly Results	
- T			Coostficity	

.

Туре	Specificity	Technique	Quantificatio	n IU/mL or Titre	Sample Type
Allo	Anti-D	IAT	Quant	4.2	Plasma

This is a clinically significant antibody.

No additional alloantibodies were detected.

Select ABO compatible, D-, C-, E-, K- red cell units for crossmatching by IAT.

There has been no significant change in antibody level.

There is a moderate risk of HDN when the maternal anti-D level is between 4 and 15 IU/mL.

This woman should be in the care of a hospital obstetric unit.

Guidelines recommend repeat testing at 4 weekly intervals to 26 weeks gestation then every 2 weeks to delivery.

At delivery a cord DAT should be performed and, if positive, the baby's Hb and bilirubin monitored.

The risk of HDN may increase if gestation proceeds beyond term.

The Others

- Tested at booking and 28 weeks
- In general a titre of >32 may possibly cause HDN
- A steep increase in titre between the two samples is worrying and may lead to further monitoring

Paternal Testing

- Determining paternal phenotype and likelihood of fetal genotype may be useful particularly when anti-D, anti-c or anti-K have been detected
- Misidentification of the father needs to be acknowledged

Fetal Genotyping

 Historically fetal DNA obtained by amniocentesis – invasive

 Fetal DNA can now be extracted from maternal peripheral plasma

Preventing HDN

- Prevent production of red cell antibodies in females of child-bearing potential
 - conservative transfusion regimes
 - transfuse D negative blood to D negative females of child bearing potential
 - and K negative blood to females of child bearing potential
- Give anti-D prophylaxis

Prophylaxis Regime

Following an event:

- <20 weeks gestation 250iu
- >20 weeks gestation at least 500iu followed by a test to measure the size of the FMH

Routine antenatal anti-D prophylaxis:

- 1500iu at 28 weeks or
- 2x500iu at 28 and 34 weeks

Following delivery of a D positive baby:

At least 500iu followed by a test to measure the size of the FMH

Difficult Interpretations

Midwives:

- Maintain a clear record of prophylactic anti-D given: dose and date.
- Inform laboratory
- Vital to take 28 week samples for group and antibody screen BEFORE giving routine prophylaxis

Laboratory:

- Identify and quantitate antibody
- Give advice on anti-D prophylaxis based on history provided and results obtained
- Request further samples at stated times to monitor the level of antibody

Sample NHSBT Report 2

		BI	ood and Transplan
	Patient:	Sample No:	
HOSPITAL TRANSFUSION LABORATORY	DoB:	NHSBT No:	
NORFOLK & NORWICH UNIVERSITY HOSPITAL	NHS No: Hospital No	Taken:	27-Jun-2012
COLNEY LANE COLNEY	Address:	Received:	02-Jul-2012 06:58:42
NORWICH NORFOLK		Reported:	03-Jul-2012
NR4 7UY		Hosp Sample I	D:
Primary Requesting Clinician: x0000001 HEAD OF BLOOD TRANSFUSION	EDD: 05-Sep-2012 Gestation 31 weeks		

Type Specificity		Technique	Quantification IU/mL or Titre		Sample Type
Not specified	Antí-D	IAT	Quant	<0.1	Plasma

No additional alloantibodies were detected.

Select ABO compatible, D-, C-, E-, K- red cell units for crossmatching by IAT.

From information provided the anti-D detected is probably due to recent anti-D prophylaxis.

No further routine screening samples are required in this pregnancy.

An antibody card has not been supplied.

Continue antenatal and post-natal anti-D prophylaxis.

Sample NHSBT Report 3

ational Blood Service - Re.	ed Cell Immunohaematolog	<u>/</u>	MB
		Blo	od and Transplant
	Patient:	Sample No:	
HOSPITAL TRANSFUSION LABORATORY	DoB: NHS No:	NHSBT No:	
GAYTON ROAD	Hospital No:	Taken:	22-May-2012
NORFOLK DE20 4ET	/100/055.	Received:	25-May-2012 08:25:48
FE30 4E I	,	Reported:	29-May-2012
		Hosp Sample ID	•
Primary Requesting Clinician: X0000001 HEAD OF BLOOD TRANSFUSION	EDD: 14-Aug-2012 Gestation 29 weeks		

O RhD negative C-c+E-e+K-

Туре	Specificity	Technique	Quantification IU/mL or Titre		Sample Type	
Not specified	Anti-D	IAT (Quant	<0.1	Plasma	

No additional alloantibodies were detected. Select ABO compatible, D-, C-, E-, K- red cell units for crossmatching by IAT.

Passive and immune anti-D cannot be differentiated at this level.

If anti-D prophylaxis has NOT been given during the past 8 weeks, repeat tests at 4 weekly intervals to 28 weeks' gestation then every 2 weeks until delivery.

If this woman has been given routine antenatal anti-D prophylaxis, no antibody screening tests are required by NHSBT after 28 weeks and continue to offer anti-D prophylaxis in accordance with national guidelines.

Please review the case and take appropriate action.

Actions

Midwives:

- If immune (allo) anti-D is present do NOT give prophylactic/passive anti-D
 - failed to prevent anti-D formation
 - must not give an unnecessary blood product
- If interpretation of results is in doubt give anti-D as
 - may prevent HDN
 - anti-D is a blood product with a good safety record
- If further samples are requested send them
 - could miss catching an immune anti-D that is increasing to a dangerous level.

Direct Antiglobulin Test (Direct Coombs Test)

- A test performed on the cord/baby's sample soon after birth
- The test to see whether an antibody is attached to an antigen on red cells (in HDN that is maternal antibody on baby's red cells)
- Under what circumstances should a DAT be tested?